Here are the DEF 14A proxy statements from Jazz Pharmaceuticals, Inc. (JAZZ) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow JAZZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAZZ filings page.
Jazz Pharmaceuticals plc is asking shareholders to vote at its 2026 annual general meeting on July 23, 2026, in Dublin. Shareholders will elect three directors, ratify KPMG as auditor, approve executive compensation on an advisory basis, and renew key share issuance authorities under Irish law.
The board seeks renewed authority to allot ordinary shares within existing authorized capital and, via a special resolution, to issue shares for cash without pre-emption rights up to 20% of issued share capital for 18 months. A separate proposal would allow adjournment if support for these capital authorities is initially insufficient.
The record date is May 28, 2026, with 62,817,628 ordinary shares entitled to one vote each. The board says 11 of 13 current directors are independent and highlights a classified board, active refreshment, strong committee structure, share ownership guidelines, an annual say‑on‑pay vote, and a Clawback Policy. Non‑employee directors receive cash retainers and annual RSU awards targeted at $400,000.